

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5: <b>C12N 15/12, 15/63, 5/10, C12Q 1/02</b>	<b>A1</b>	(11) International Publication Number: <b>WO 95/04144</b> (43) International Publication Date: <b>9 February 1995 (09.02.95)</b>
(21) International Application Number: <b>PCT/US94/08589</b> (22) International Filing Date: <b>29 July 1994 (29.07.94)</b> (30) Priority Data: <b>08/100,740 30 July 1993 (30.07.93) US</b> (71) Applicant: <b>NEUREX CORPORATION [US/US]; 3760 Haven Avenue, Menlo Park, CA 94025 (US).</b> (72) Inventors: <b>HORNE, William, A.; 15 Shelford Avenue, San Carlos, CA 94070 (US). BELL, John, R.; 647 Martinique Drive, Redwood City, CA 94065 (US). CONG, Ruth; 23 Park Boulevard, Oakland, CA 94606 (US). HASHIMOTO, Chika; 1027 Berkeley Avenue, Menlo Park, CA 94025 (US). PALMA, Andrew; 501 Saddle Creek Court, San Ramon, CA 94583 (US). PHILIP, Mohan; 204 Newcastle Court, Redwood City, CA 94061 (US). ZHOU, Mei; Apartment 6, 1466 San Antonio Street, Menlo Park, CA 94025 (US).</b> (74) Agent: <b>DEHLINGER, Peter, J.; Dehlinger &amp; Associates, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).</b>	(51) Designated States: <b>JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b>  <b>Published</b> <i>With international search report.</i>	
(54) Title: <b>DNA ENCODING A HUMAN CALCIUM CHANNEL ALPHA-1E SUBUNIT</b> (57) Abstract <p>Isolated DNA encoding a human neuronal calcium channel alpha-1 subunit of subtype E and its corresponding polypeptide are disclosed. Also disclosed are cells expressing the human neuronal calcium channel alpha-1E subunit, as well as methods for screening for therapeutic compounds, using such compositions.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## DNA ENCODING A HUMAN CALCIUM CHANNEL ALPHA-1E SUBUNIT

### Field of the Invention

The present invention relates to human  
5 calcium channel compositions. In particular, the  
invention includes compositions containing a human  
neuronal calcium channel alpha subunit designated  
subtype "1E" herein. Compositions of the invention  
include coding sequences for the subunit, as well  
10 as cells containing such coding sequences and  
expressing the human neuronal alpha-1E subunit.

### References

- Ausubel, F.M., et al. (1992) Current  
15 Protocols in Molecular Biology, John Wiley and  
Sons, Media, PA.  
Dubel, et al. (1992) *Proc. Natl. Acad. Sci.*  
89:5058-5062.  
Harpold, M.M., et al. (1993) PCT Patent  
20 Application Pub. No. WO 93/04083.  
Hulin, R., et al. (1990) *EMBO J.* 11:885-890.  
Mintz, I.N., et al. (1991) *Proc. Natl. Acad.*  
*Sci. USA* 88:6628-6631.  
Mori, T, et al. (1991) *Nature* 350:398-402.  
25 Sambrook, et al. (1989) Molecular Cloning. A  
Laboratory Manual, Cold Spring Harbor Laboratory  
Press.  
Scharf, S. J., et al., *Science* 233:1076  
(1986).  
30 Snutch, T.P., et al. (1990) *Proc. Natl. Acad.*  
*Sci. USA* 87:3391-3395.  
Tanabe, T. et al (1987) *Nature* 328:313-318.  
Tsien, R.W., et al. (1991) *TIPS* 12:349-354.  
Williams, M. E. et al. (1992) *Neuron* 8:71-84.

35

### Background of the Invention

Voltage-gated calcium channels are present in  
a wide variety of tissues, particularly excitable  
tissues, where they act to regulate membrane

excitability. Such functions as muscle contraction and synaptic transmission are regulated, at least in part, by specific voltage-gated calcium channels. Compounds, such as

5 dihydropyridine compounds, that block certain of these channels are used therapeutically in the management of various disorders such as hypertension, angina and subarachnoid hemorrhage.

Voltage-gated calcium channels have generally

10 been classified according to their electrophysiological and pharmacological properties. Currently, at least four classes of voltage-gated calcium channels are recognized: L-type, T-type, N-type, and P-type. However,

15 molecular cloning techniques have revealed the existence of different sub-types of channel within some of these classes. (see Tsien et al., Trends in Pharmacological Sciences 12: 349-354, for review).

20 In general, voltage gated calcium channels have been shown to consist of at least 4 non-identical subunits: the alpha-1 subunit, alpha-2 subunit, beta subunit and gamma subunit. For the L-type calcium channels, which are probably the

25 best characterized calcium channels, it has been shown that the alpha-1 subunit contains the binding site for dihydropyridine ligands.

Partial cDNA clones encoding portions of several different subtypes of of the rat neuronal calcium channel alpha-1 subunit, referred to as

30 rat brain class A, B, C and D, were first isolated from rat brain cDNA libraries (Snutch, et al., 1990). Homologous alpha-1 clones subtypes A-D have been described in humans by Harpold et al.

35 (PCT/US92/06903; WO93/04083).

The present invention is concerned with a fifth human neuronal calcium channel alpha-1

subunit, termed "1E" or hc-1E herein. This subunit diverges considerably from the other human alpha-1 subunit clones, exhibiting only about 62% deduced amino acid sequence homology to other human neuronal alpha-1 subunits. As shown herein, this subunit can form a heterologous calcium channel with alpha-2 and beta subunits. The novel channel has a unique pharmacology and is therefore useful in screening for new, more selective therapeutic agents directed at calcium channel modulation.

#### Summary of the Invention

In one aspect, the invention includes an isolated DNA fragment that encodes an alpha-1E subunit of a human neuronal calcium channel. The fragment has the nucleotide sequence presented as SEQ ID NO:1.

Also included in the invention is an alpha-1E polypeptide subunit of a human neuronal calcium channel having the sequence presented as SEQ ID NO:2. In another aspect, the invention includes a mammalian expression vector containing the nucleotide sequence SEQ ID NO:1.

A eukaryotic cell in accordance with the invention includes a heterologous DNA having the sequence presented as SEQ ID NO:1. The cell expresses a neuronal calcium channel including a polypeptide subunit having the sequence SEQ ID NO: 2. The cells may be further designed to express neuronal calcium channel subunits  $\alpha_2$  and  $\beta$ .

The cell line can be used to screen compounds effective to inhibit calcium uptake by neuronal cells.

These and other objects and features of the invention will be more fully appreciated when the following detailed description of the invention is

read in conjunction with the accompanying drawings.

#### Brief Description of the Drawings

5        Figure 1 shows the DNA sequence (SEQ ID NO: 1) of the human neuronal calcium channel alpha subunit  $\alpha$ -1E and the deduced amino acid sequence (SEQ ID NO: 2) for the channel subunit; and

10        Figure 2 shows a tracing of a barium current measured in a eukaryotic cell expressing a heterologous calcium channel including the human neuronal calcium channel alpha subunit  $\alpha$ -1E.

#### Detailed Description of the Invention

##### 15    I. Definitions

Unless otherwise indicated, all terms used herein have the same meaning as they would to one skilled in the art of the present invention. Practitioners are particularly directed to

20    Current Protocols in Molecular Biology (Ausubel) for definitions and terms of the art.

The terms "heterologous DNA" and "heterologous RNA" refer to nucleotides that are not endogenous to the cell or part of the genome in which they are present; generally such  
25    nucleotides have been added to the cell, by transfection, microinjection, electroporation, or the like. Such nucleotides generally include at least one coding sequence, but this coding  
30    sequence need not be expressed.

The term "expression vector" refers to vectors that have the ability to incorporate and express heterologous DNA fragments in a foreign cell. Many prokaryotic and eukaryotic expression  
35    vectors are commercially available. Selection of appropriate expression vectors is within the knowledge of those having skill in the art.

## II. Isolation of DNA Coding Sequences for Human Neuronal Alpha-1E Subunit

The diversity of voltage-gated calcium channels between and within tissues as well as across species is becoming more apparent, as new channels having distinct electrophysiological and pharmacological characteristics are reported. The present invention describes a new calcium channel isolated from human brain. As reported herein, this channel is categorized as an alpha subunit of a voltage-gated calcium channel. The novel human channel reported herein is referred to as the human alpha-1E subunit, or  $\alpha$ -1E, in accordance with the nomenclature defined by Snutch for rat brain-derived calcium channel alpha subunits A-D.

A number of overlapping partial cDNA clones were isolated from a human hippocampal library in order to characterize the complete  $\alpha$ -1E coding sequence. The complete  $\alpha$ -1E nucleotide (nt) sequence is depicted in Figure 1 as SEQ ID NO: 1. Also shown is the deduced amino acid sequence (single letter code indicated below nt sequence) as SEQ ID NO: 2. A list of the of four partial cDNA clones used to characterize the  $\alpha$ 1E sequence and the nucleotide position of each clone relative to the full-length  $\alpha$ -1E sequence (SEQ ID No.1) is shown in Table 1 below.

Table 1  
Identification of Partial  $\alpha$ -1E Clones

Name	SEQ ID NO	Location Relative To Full-length Sequence
H24	3	nt 1 to 2374 of SEQ ID No 1
H6	4	nt 1185 to 5377 of SEQ ID No 1
I2	5	nt 3192 to 6435 of SEQ ID No 1
3-69A	6	nt 5176 to 6922 of SEQ ID No 1

The isolation and characterization of each of the partial clones are described below and detailed in Example 1. The codon for the start methionine begins with nt 107 and nt 6912 represents the end of the open reading frame. The initial 107 and final 10 nucleotides (nt) represent 5' and 3' untranslated regions, respectively.

10        A.    Screening Libraries for Human Calcium Channels

Synthetic oligonucleotide probes for hybridization screening were prepared on an automated oligonucleotide synthesizer (Applied Biosystems, Foster City, CA). In order to obtain clones to form the complete  $\alpha$ -1E sequence, oligonucleotide probes based on other calcium channels were constructed as described in Example 1. Probes were constructed based on the sequence of the rat calcium channels such as those described by Snutch and Dubel. These subunits are  $\alpha$ -1 subunits of rat neuronal calcium channels. They exhibit only about a 62% amino acid sequence identity with the  $\alpha$ -1E clone which was eventually constructed. Further probes were restriction fragments of partial clone H6.

A human hippocampal library was obtained from a commercial supplier (Stratagene, La Jolla, CA). Alternatively, brain libraries from the hippocampal or other discrete brain regions, or from the whole brain, can be produced according to standard methods now known in the art (Ausubel), in order to identify variants, such as splice variants of the  $\alpha$ -1E channel. Such methods include lysing of cells comprising the region of interest to extract RNA. PolyA+ RNA is then isolated and used to synthesize single-stranded cDNA, from which is produced double-stranded cDNA,



using specific r random hexamer primers, such as hexadeoxynucleotide primers (Clontech, Palo Alto, CA).

Restriction enzyme adaptor regions are then  
5 ligated to the single-stranded cDNA, according to standard methods (Sambrook). Such cDNA is then purified and size-selected by agarose gel chromatography. The cDNA is then eluted and  
10 ligated to a selected vector sequence, such as a lambda gt11 vector or a lambda ZAP vector, as used in the Examples reported herein. The vector is then packaged into appropriate phage hosts and used to infect bacterial cells, as E.coli according to methods known in the art.

15 Commercial or custom generated libraries, such as phage-cDNA libraries described above, are screened using as probes oligonucleotide hybridization probes, as described in Example 1, under standard conditions, and medium stringency  
20 (Ausubel). Briefly, oligonucleotide hybridization probes are radiolabeled by random priming methods (Sambrook), then hybridized to immobilized DNA from the cDNA library. Those phage plaques showing hybridization with the probes are  
25 selected, subcloned, and re-tested. Positive clones are identified by autoradiography. Clones identified according to the methods described above are expected to be partial sequence clones, due to the size selection of the cDNA used in  
30 generating the library and the predicted size of the calcium channel alpha subunit, based on data from calcium channels from other species.

Clones identified and isolated as described above are plaque purified prior to extraction of  
35 DNA and production of double stranded plasmid cDNA. The sequence of the plasmid cDNA is then determined, by standard methods, such as on a

commercial DNA sequencer (Applied Biosystems, Foster City, CA). As noted above, four partial clones, H6, H24, I2, and 3-69A, were used to determine the full-length sequence of  $\alpha$ -1E.

- 5 Regions of overlap between different clones obtained were determined by comparison of the sequences.

- Alternatively, the sequences provided by the end-terminal sequences of partial clones useful as specific sequence primers in first-strand DNA synthesis reactions (Maniatis et al.; Scharf et al.) using, for example, partially purified total cellular RNA as substrate. Synthesis of the second-strand of the cDNA is randomly primed (Boehringer Mannheim, Indianapolis IN). The above procedures identify or produce cDNA molecules corresponding to nucleic acid regions that are adjacent to any of the partial clone sequences. These newly isolated sequences can in turn be used to identify further flanking sequences, and so on, to identify overlapping cDNA clones from which the entire  $\alpha$ -1E sequence can be determined. Using the general methods described above, and detailed in Example 1, the sequence of the full-length  $\alpha$ -1E coding sequence is determined. The full-length  $\alpha$ -1E clone is constructed from the partial overlapping clones is detailed in Example 2.
- 10  
15  
20  
25

30 B. Construction of Full-length  $\alpha$ -1E Clones

- With reference to Table 1 and Figure 1, it can be seen that  $\alpha$ 1E cDNA clones H24, H6, I2, and 3-69A, isolated as described above, overlap and include the nucleotide sequence which codes for the entire  $\alpha$ 1E open reading frame, nt 107 to 6912 (SEQ ID No: 1). Restriction fragments of these partial cDNA clones were ligated together to
- 35

generat a full-length  $\alpha 1E$  cDNA in a eukaryotic expression vector (p DNA III- Invitrogen). The resulting construct was named NX-HE1.

The construction of  $h\alpha$ -1E, termed NX-HE1 and identified as SEQ ID NO: 1, herein, was performed in multiple steps as described in detail in Example 2. Briefly, the H24 clone (SEQ ID NO:3) was recloned into Bluescript SK+ ("BS") (Stratagene, San Diego, CA) to obtain proper orientation within the BS polylinker such that the BS XhoI site was 5' relative to the coding region, forming Construct 1. An XhoI fragment from Construct 1 was then ligated into the eukaryotic expression vector pcDNA III (Invitrogen, San Diego, CA) to form Construct 2. An XhoI/ApaI fragment from clone H6 (SEQ ID NO: 4) was then ligated into Construct 2 form Construct 3. The remainder of the 3' end was constructed separately, as follows. An SfiI/BamHI fragment from clone 3-69A was ligated into clone I2 (SEQ ID NO: 5) to form Construct 4. Finally, an ApaI fragment of Construct 4 was ligated into Construct 3 to from the full length clone SEQ ID No.1). This ligated product containing the full length sequence was named NX-HE1.

### III. Heterologous Expression of $h\alpha$ -1E in Cells

It can be appreciated that, given the diversity and importance of voltage-gated calcium channels in mammalian physiology, possession of cells which transiently or constitutively express selected channel subtypes, such as the  $h\alpha$ -1E subtype calcium channel, would find use in the medical arts, particularly in the areas of diagnosis and/or drug screening. Exemplary assays in these areas are described in Section V.

It can be appreciated that functional expression of calcium currents is particularly useful in practicing parts of the invention described herein. However, expression of a particular heterologous DNA sequence can be monitored to some advantage, using non-functional assays, such as Northern blot assays and protein expression assays, such as immunodetection methods. The present invention provides tools for use in such methods, including oligonucleotide probes and proteins and peptides for production of antibodies for use in immunodetection assays.

A. Preparation of Recombinant Eukaryotic Cells Containing DNA Encoding Heterologous  $\alpha$ -1E Subunits

DNA encoding the  $\alpha$ -1E calcium channel subunit may be introduced into a host cell for expression of the DNA. Methods for introduction of such DNA into cells are known those skilled in the art (Ausubel, Sambrook). Such methods include, for example, transfection of eukaryotic cells with an appropriate expression plasmid vector, such as the vectors described in Section II herein, or a combination of plasmid vectors each containing a different calcium channel subunit, selected from  $\alpha$ -1,  $\alpha$ -2,  $\beta$ , and  $\gamma$  subunits known in the art to form functional calcium channels (Williams). each encoding one or more distinct genes or with linear DNA, and selection of transfected cells are also well-known in the art (Sambrook, et al., 1989).

Cloned full-length DNA encoding the  $\alpha$ -1E subunit of a human calcium channel, such as the  $\alpha$ -1E DNA sequence SEQ ID NO: 1, described herein, introduced into a plasmid vector for expression in a eukaryotic cell. Host cells may also be

transfected with linear DNA according to standard methods.

Practice of the present invention can be effectively carried out using any of a number of  
5 mammalian expression systems, including yeast cells. However, mammalian expression systems may be preferred for practicing certain aspects of the invention.

Eukaryotic cells suitable for introduction of  
10 heterologous  $\alpha$ -1E calcium channel subunit include any cells that are transfectable by such DNA or RNA or into which such DNA may be injected. Preferred host cells are those that can also express the heterologous DNA and RNA. For  
15 practicing certain aspects of the invention, such as electrophysiological measurements described in Section IV it is appreciated that it may be desirable that the host cell lack endogenous functionally expressed voltage gated calcium  
20 channelse having current characteristics similar to those exhibited by the human  $\alpha$ -1 calcium channel subunits described herein. In such cases it may be necessary, in order to observe and measure functional expression of the exogenously  
25 added  $\alpha$ -1E subunit, to introduce into the cell heterologous coding sequences encoding the  $\alpha$ -2 and possibly also the beta calcium channel subunit. As described above, coding sequences for such auxilliary subunits have been published, and  
30 expression in vectors suitable for introduction into cells is well within the skill of the practitioner.

In addition, preferred cells for introducing DNA include those that can be transiently or  
35 stably transfected and include, but are not limited to, cells of mammalian origin, such as COS cells, mouse 1 cells, Chinese Hamster Ovary (CHO)

cells, human embryonic kidney (HEK) cells, African green monkey cells, and the like. Preferred cells include DG44 cells and HEK 293 cells, particularly HEK 293 cells that have been adapted for growth in suspension. Additionally *Xenopus laevis* oocytes find use in the practice of the invention, as described in Part B and Section IV, below. Additionally, yeast cells such as *Saccharomyces cerevisiae* or *Pichia pastoris* may be utilized in practicing the invention.

Heterologous DNA encoding a human  $\alpha$ -1E subunit, such as the  $\alpha$ -1E calcium channel subunit, may be introduced by any method known to those skilled in the art, such as transfection with a vector containing the DNA sequence that encodes the subunit, such as the DNA sequence SEQ ID NO: 1. Particularly preferred vectors for transfection of mammalian cells are the pSV2dhfr expression vectors, which contain the SV40 early promoter, mouse dhfr gene, SV40 polyadenylation and splice sites and sequences necessary for maintaining the vector in bacteria, cytomegalovirus (CMV) promoter-based vectors such as pCMV or pCDNA1 or pCDNA3 (Invitrogen), and MMTV promoter-based vectors. DNA encoding the human calcium channel subunit  $\alpha$ -1E is been inserted in the vector pCDNA3 such that its expression is regulated by the CMV promoter. Such constructs are suitable for transfecting a number of mammalian cells, including COS cells and HEK 293 cells. Other suitable vectors and cell targets include, but are not limited to pCMV and pREP vectors (obtained from Invitrogen, San Diego, CA).

Stably or transiently transfected mammalian cells may be prepared by methods that are well known in the art. Cells are transfected with an expression vector having a selectable marker gene

such as the gene for thymidine kinase, dihydrofolate reductase, or the like. Stable transfection of cells is conveniently achieved by growing the transfected cells under conditions that promote growth of cells expressing the marker genes.

The heterologous DNA encoding the human alpha-1E calcium channel subunit may be integrated into cell's chromosomal material or may be maintained in the cell as an episomal element. Cells containing such heterologous DNA may be passaged and/or subcultured, according to methods appropriate to the cell type and known in the art.

15        B.    Functional Expression of  $\alpha$ -1E in *Xenopus* oocytes

A plasmid, such as a pBluescript SK+ plasmid, containing the full-length NX-HR1 coding sequence is used to produce complementary RNA, using an appropriate RNA polymerase, such as T7 or SP6 polymerase. Such RNA is injected into oocytes from *Xenopus laevis* (about 5-10 pg/oocyte), according to methods known in the art. For expression of a functional calcium channel in oocytes, coexpression of a calcium channel alpha-2 subunit, such as the rabbit skeletal muscle alpha-2 subunit (Mori et al., incorporated herein by reference) may be required. Additionally, inclusion of a calcium channel Beta subunit, such as the Beta-3 subunit from rabbit heart (Hulin et al., incorporated herein by reference), helps optimize functional expression of the channel. Coding sequences for the aforementioned alpha-2 and beta-3 subunits have been published as cited above, and construction of expression vectors suitable for injection into oocytes is within the skill of the practitioner. For expression in

o cytes, approximately equimolar amounts of RNA are injected into each oocyte.

C. Functional Expression of  $\alpha_1$ -IE in Mammalian Cells

One cell type that is particularly amenable to transient or stable transfection is the human embryonic kidney cell line HEK 293 (ATCC Accession No. CRL1573). Such cells can be transiently cotransfected with the  $\alpha_1$ -IE subunit cDNA expression plasmid, and one or more of an  $\alpha_2$  calcium channel subunit cDNA expression plasmid, an  $\beta_1$  subunit cDNA expression plasmid as detailed in Example 4 (Williams).

Stable transfection can also be achieved in HEK 293 cells according to standard methods (Ausubel). Suitable vectors for stable transfection include pCDNA1 and pCDNA3.

Transfected cells are selected, for example by differential growth in limiting medium, according to methods known in the art. Such cells are subcloned and tested, for example by Northern blot analysis, for the evidence for the expression of the human  $\alpha_1$ -IE calcium channel.

Alternatively or in addition, individual transfected cells can be analyzed electrophysiologically for the presence of voltage-activated calcium currents (using barium as carrier, as described in Section IV. Such cells are useful in functional and/or binding assays, as described in Section V.

IV. Electrophysiological Measurements

A. Recording of Calcium currents in *Xenopus* oocytes

Functional expression of a heterologous  $\alpha_1$ -IE calcium channel subunit can be measured in *Xenopus* oocytes injected with heterologous RNA, as



15

described in Section III. Currents are conveniently recorded using a standard two-microelectrode voltage-clamp connected to an amplification system. Cells are placed in a chloride-free bathing solution containing about 40 mM  $\text{Ba}(\text{OH})_2$ , such that barium acts as current carrier in the system. Channels are activated by periodic delivery of voltage pulses. Currents are measured and normalized according to procedures known to those familiar with the art pertaining to electrophysiology.

#### V. Utility

The present invention includes methods for identifying therapeutic compounds, such as calcium channel agonist and antagonists, that modulate the activity of calcium channels. Such assays are useful as screens for new therapeutic compounds having calcium channel agonist and/or antagonist activity. Presently, calcium channel antagonists directed at L-type calcium channels find use in the treatment of hypertension, subarachnoid hemorrhage and variant forms of angina. Certain N-type calcium channel antagonists have been found to be useful in reducing cerebral ischemia, as described in co-owned U.S. Patents 4,051,403 and 5,189,020, incorporated herein by reference.

According to the present invention, eukaryotic cells expressing heterologous  $\alpha_1\text{-IE}$  calcium channel subunits encoded by heterologous DNA as described herein are useful for screening for  $\alpha_1\text{-IE}$  subtype-specific compounds, and for predicting the relative potencies of such compounds.

In particular, cells expressing such heterologous calcium channels of the  $\alpha_1\text{-IE}$  subtype can be used in binding assays, wherein whole cells

or membranes thereof are tested for ability to bind a test compound, generally by measuring the ability of the test compound to displace a known ligand of the channel. One appropriate functional ligand which binds to the channel and blocks  $h\alpha$ -1E calcium currents is the spider toxin Aga-IIIa (isolated as described by Mintz, et al., incorporated herein by reference).

Methods for carrying out such screening assays are well known in the art, and setting up such assays is within the skill of the practitioner. Co-owned allowed U.S. patent application 07/855,269, incorporated herein by reference, describes assays which utilize isolated neuronal calcium channels for screening of certain types of N-type calcium channel antagonists. Such methods are adaptable to the present invention.

Alternatively, or additionally, such screening assays may include assays in which is determined the functional activity of an expressed calcium channel. In such an assay, drugs which alter such activity, such as calcium current activity, are candidates for calcium channel-based therapeutics, of the types suggested above or or additional types.

The following examples illustrate, but in no way are intended to limit the present invention.

#### 30 Materials and Methods

A lambda-ZAP cDNA human hippocampal cDNA library was obtained from Stratagene (La Jolla, CA). A eukaryotic expression vector pcDNA III was obtained from Invitrogen (San Diego CA). T4 DNA ligase and T4 DNA polymerase were obtained from New England Biolabs (Beverly, MA); Nitrocellulose.

17

filters were obtained from Schl ichter and Schuell  
(Keen , NH).

Bluescript SK+(BS) was obtained from  
Stratagene (San Diego, CA).

5 Dephosphorylated Calf intestinal phosphatase  
(CIP) was obtained from New England Biolabs  
(Beverly, MA).

Synthetic oligonucleotide linkers and primers  
were prepared using commercially available  
10 automated oligonucleotide synthesizers, such as  
obtained from Applied Biosystems (Foster City,  
CA). Alternatively, custom designed synthetic  
oligonucleotides may be purchased, for example,  
from Synthetic Genetics (San Diego, CA). cDNA  
15 synthesis kit and random priming labeling kits  
were obtained from Boehringer-Mannheim Biochemical  
(BMB, Indianapolis, IN).

Standard molecular biology and cloning  
techniques were performed essentially as  
20 previously described in Ausubel, et al., Sambrook,  
et al., and Maniatis, et al.

#### Example 1

##### Isolation of partial cDNA clones

###### 25 A. Clone H6

One million recombinants of a  $\lambda$ ZAP II  
(Stratagene, La Jolla, CA) human hippocampal cDNA  
library were screened in duplicate at a density of  
50,000 plaques per 150 mm plate using two  
30 radiolabeled 1.6 kb (Hind III and Xho I digested)  
fragments of the rat Class B  $\alpha$ 1 subunit cDNA (for  
the sequence of the rat Class B  $\alpha$ 1 subunit see  
Dubel et al. (1992) Proc. Natl. Acad. Sci.  
89:5058-5062, incorporated herein by reference):

35

Fragment	Approx. Size
HindIII-HindIII	712 to 2288
XhoI-XhoI	3793-5394

5           The hybridization was performed under standard conditions (5x SSPE, 5X Danhardt's, 0.1% SDS, 1 mg/ml salmon sperm DNA; recipes found in Sambrook et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press). Filters were washed under medium stringency conditions (0.2X SSPE, 0.1% SDS, 50°C). H6 was one of two Class E specific clones isolated. H6 bacteriophage was plaque purified using standard methods (J. Sambrook et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press), double stranded BS plasmid cDNA was isolated using standard phagemid rescue procedures (Stratagene), and DNA sequence was obtained using PCR based fluorescence dye terminator procedures (Applied Biosystems).

#### B. Clone H24

One million recombinants of a  $\lambda$ ZAP II (Stratagene) human hippocampal cDNA library were screened in duplicate at a density of 50,000 plaques per 150 mm plate using a radiolabeled NotI/EcoRI fragment (nucleotides 118 to 705) of the rat Class B  $\alpha 1$  subunit cDNA (for the sequence of the rat Class B  $\alpha 1$  subunit see Dubel et al. (1992) Proc. Natl. Acad. Sci. 89:5058-5062). The hybridization was performed under standard conditions. Filters were washed under medium stringency conditions H24 was one of 5 positives isolated in the screen (4 of which were Class E clones). H24 bacteriophage was plaque purified,

19

double standard plasmid cDNA was prepared, and the clone was characterized by DNA sequencing.

C. Clone I2

5 One million recombinants of a  $\lambda$ ZAP II (Stratagene) human hippocampal cDNA library were screened in duplicate at a density of 50,000 plaques per 150 mm plate using a radiolabeled PstI/ ApaI fragment (nucleotides 4194 to 4740)  
10 from the cDNA fragment H6. The hybridization was performed under standard conditions. Filters were washed under medium stringency conditions. I2 was one of 13 positives isolated in the screen. I2 bacteriophage was plaque purified, double standard  
15 plasmid cDNA was prepared, and the clone was characterized by DNA sequencing.

D. Clone 3-69A

20 One million recombinants of a  $\lambda$ ZAP II (Stratagene) human hippocampal cDNA library were screened in duplicate at a density of 50,000 plaques per 150 mm plate using a radiolabeled DNA oligonucleotide probe derived from a rat neuronal alpha subunit cDNA. The hybridization was  
25 performed under standard conditions. Filters were washed under medium stringency conditions. 3-69A was one of 37 positives isolated in the screen. 3-69A bacteriophage was plaque purified, double standard plasmid cDNA was prepared, and the clone  
30 was characterized by DNA sequencing.

Example 2

Construction of full length Human  $\alpha$ 1E cDNA

35  $\alpha$ -1E cDNA clones H24, H6, I2, and 3-69A overlap and include the nucleotide sequence which codes for the entire  $\alpha$ -1E open reading frame, nt 107 to 6912 (SEQ ID No: 1). Restriction

fragments of these partial cDNA clones were ligated together to generate a full-length ha-1E cDNA in a eukaryotic expression vector (pcDNA III-Invitrogen). The resulting construct was named

- 5 NX-HE1. The construction of NX-HE1 was performed in multiple steps as described in detail below: 1) recloning of H24 into Bluescript SK+(BS) to obtain proper orientation (Construct 1), 2) ligation of an XhoI fragment (nt 1 to 1374) from Construct 1  
10 into pcDNA III (to form Construct 2), 3) ligation of an XhoI/ApaI fragment from H6 (nt 1374 to 4181) into Construct 2 (to form Construct 3), 4) ligation of an SfiI/BamHI fragment from 3-69A (nt 5884 to 3' untranslated) into I2 (to form  
15 Construct 4), and 5) ligation of an ApaI fragment (nt 4181 to 3' untranslated into Construct 3 to from the full length clone SEQ ID No.1).

- 1) To obtain Construct 1, H24 was digested with EcoRI and religated into EcoRI digested BS.  
20 The purpose of this ligation was to reorient the original H24 clone within the BS polylinker such that the BS XhoI site was 5' relative to the coding region.

- 2) Construct 2 was digested with XhoI and the  
25 resultant 1.4 kb fragment was purified from an agarose gel and ligated into XhoI digested pcDNAIII dephosphorylated with calf intestinal phosphatase (CIP). This construct thus contained the 5' end of the clone (nt 1 to 1374).

- 30 3) H6 was then digested with XhoI and Apa I and the resultant 2.8 kb fragment (nt 1374 to 4181) was ligated into XhoI /ApaI digested and CIP treated Construct 2. The ligated product was referred to as Construct 3.

- 35 4) The remainder of the 3' end was constructed separately. First, 3-69A was digested with SfiI and BamHI to yield a 2.7 kb fragment (nt

5884 to 3' untranslated), which was gel purified and ligated into SfiI/BamHI digested and CIP treated I2. The ligated product was referred to as Construct 4. (All ligation junctions were  
5 sequenced prior to proceeding with the next step).

5) The final construct was prepared by digesting Construct 4 with ApaI, yielding a 4.1 kb fragment (nt 4182 to 3'ut) which was gel purified and ligated into ApaI cut CIP treated  
10 Construct 3. This ligated product containing the full length sequence was named NX-HE1.

### Example 3

#### Functional Expression of $\alpha$ -1E in *Xenopus* oocytes

15 The  $\alpha$ -1E full-length DNA sequence SEQ ID NO:1 was subcloned into pBluescript SK+ to obtain plasmid p $\alpha$ -1E(SK+). Complementary RNA was synthesized from the plasmid in vitro using T7 or SP6 polymerase. Additionally, complementary RNA  
20 is synthesized from plasmids containing calcium channel  $\alpha$ -2 subunits and Beta subunits known in the art (Mori, Williams, Tanabe). RNA from each subunit was injected in equimolar ratios using 0.1  $\mu$ g ml<sup>-1</sup>  $\alpha_1$ , 0.1  $\mu$ g ml<sup>-1</sup>  $\alpha_2$ , and 0.03  $\mu$ g ml<sup>-1</sup>  $\beta$ ; - 50 nl is injected per cell. The  $\alpha$ -1E  
25 currents were recorded by a standard two-microelectrode voltage-clamp using a Warner amplifier (OC-725A) in a chloride free bath solution, containing (in mM): Ba(OH)<sub>2</sub>, 5;  
30 tetraethylammonium-OH, 40; KOH, 2; HEPES, 5; pH 7.4 adjusted with methanesulphonic acid. Data were sampled at 10 kHz and filtered at 2 kHz. Leak and capacitance currents are subtracted off-line by a P/4 protocol. Voltage pulses are  
35 delivered every 15 s. For steady-state inactivation experiments, voltage pulses were delivered every 20 s. Peak normalized currents

were fitted to a Hodgkin-Huxley inactivation curve. Figure 2 shows a trace of a barium current measured in a *Xenopus* oocyte previously injected with mRNA encoding the human calcium channel subunit  $\alpha$ -1E (SEQ ID NO:2) plus RNA encoding alpha-2 and beta subunits, as described above. The current was invoked from a holding potential of -80 mV to a test potential of 0mV.

The spider toxin AgalIIIA was effective to block this current, at a batch concentration of 50 nM. Other calcium channel blocking compounds which were unable to block this current and maximum concentrations tested are as follows: omega conotoxins MVIIA (5  $\mu$ M), MVIIC (5  $\mu$ M), TVIA (5  $\mu$ M), Aga IVA (100 nM) and dehydropyridines.

#### Example 4

##### Expression of $\alpha$ -1E in Mammalian Cells

Human embryonic kidney cells (HEK 293 cells) were transiently and stably transfected with human neuronal DNA encoding calcium channel subunits.

##### A. Transfection of HEK 293 Cells

Separate expression vectors containing DNA encoding human neuronal calcium channel  $\alpha$ -1E, rat  $\alpha_1$ , and  $\beta_1$  subunits, were used. constructed as described in Example 2. The  $\alpha$ -1E coding sequence described herein as SEQ ID NO: 1 was incorporated into a pCDNA1+3 vector, as described above, with addition of a c-myc epitope tag on the 5' end of the  $\alpha$ -1E coding sequence, for monitoring, according to established methods. The vector was used for stable transfection of HEK 293 cells using the calcium phosphate transfection procedure (Ausubel). Culture plates containing about two million HEK 293 cells, were transfected with 1 ml



of DNA/calcium phosphate precipitate containing 5  
µg of each of the vectors. After 10-20 days of  
growth in media containing 500 µg G418, colonies  
had formed and were isolated according to standard  
5 procedures.

Expression of hα-1E subunit by cells was  
monitored by fluorescence immunolabeling. Cells  
were incubated with fluorescently tagged antibodies  
(from commercial sources) directed to the c-myc  
10 epitope, the coding sequence for which was added  
to the 5' end of the hα-1E coding sequence.  
Expression of the hα-1E subunit having the epitope  
was evidenced by immunofluorescence.

15

While the invention has been described with  
reference to specific methods and embodiments, it  
will be appreciated that various modifications and  
changes may be made without departing from the  
20 invention.

## IT IS CLAIMED:

1. An isolated DNA fragment, comprising a sequence of nucleotides that encodes an alpha-1E subunit of a human neuronal calcium channel, and having the sequence presented as SEQ ID NO:1.
2. An alpha-1E polypeptide subunit of a human neuronal calcium channel having the sequence presented as SEQ ID NO:2.
3. A mammalian expression vector containing the nucleotide sequence presented as SEQ ID NO:1.
4. A eukaryotic cell, which includes a heterologous DNA having the sequence presented as SEQ ID NO:1.
5. The cell of claim 4, wherein the cell is a *Xenopus oocyte*.
6. The cell of claim 4, wherein the cell is a human embryonic kidney cell.
7. The cell of claim 4, wherein said DNA expresses a neuronal calcium channel including a polypeptide subunit having the sequence presented as SEQ ID NO: 2.
8. The cell line of claim 7, which further expresses neuronal calcium channel subunits  $\alpha$ , and  $\beta$ .
9. A method of screening a compound capable of blocking calcium uptake in human neuronal cells, comprising

25

exposing the cell of claim 7 with the test compound,

examining the effect of said exposing on calcium uptake into the cells, and

5 selecting the compound if said exposing inhibits calcium uptake into the cells.

10. The method of claim 9, wherein said exposing includes contacting the cells with the  
10 cell of claim 8.